Cytosorbents Crp Stock Operating Margin

CTSO Stock

USD 0.92 0.06 6.12%

Cytosorbents Crp fundamentals help investors to digest information that contributes to Cytosorbents Crp's financial success or failures. It also enables traders to predict the movement of Cytosorbents Stock. The fundamental analysis module provides a way to measure Cytosorbents Crp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytosorbents Crp stock.

		Last Reported	Projected for Next Year
	Operating Profit Margin	(0.84)	(0.88)

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cytosorbents Crp Company Operating Margin Analysis

Cytosorbents Crp's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

Operating Income

Revenue

100

More About Operating Margin | All Equity Analysis

Current Cytosorbents Crp Operating Margin

(1.02) %

Most of Cytosorbents Crp's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytosorbents Crp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Cytosorbents Operating Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for Cytosorbents Crp is extremely important. It helps to project a fair market value of Cytosorbents Stock properly, considering its historical fundamentals such as Operating Margin. Since Cytosorbents Crp's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cytosorbents Crp's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cytosorbents Crp's interrelated accounts and indicators.

	Total Assets	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Total Stockholder Equity	Common Stock	Accounts Payable	Good Will	Intangible Assets	Property Plant Equipment	Long Term Debt	Net Receivables	Short Term Debt	Net Tangible Assets	Current Deferred Revenue	Capital Surpluse	Short Long Term Debt	Long Term Debt Total	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.68	-0.78	0.62	0.92	0.93	-0.35	0.69	0.89	0.94	0.77	0.39	0.86	0.04	0.95	0.63	0.9	0.63	0.85	0.76	0.91	0.77	0.79
Net Debt	-0.68		0.17	0.05	-0.89	-0.86	0.17	-0.07	-0.33	-0.43	-0.15	-0.15	-0.29	0.31	-0.81	-0.28	-0.42	-0.31	-0.39	-0.2	-0.87	-0.98	-0.25
Retained Earnings	-0.78	0.17		-0.84	-0.56	-0.55	0.28	-0.82	-0.92	-0.89	-0.78	-0.42	-0.92	-0.37	-0.61	-0.56	-0.89	-0.59	-0.81	-0.86	-0.51	-0.26	-0.81
Total Liab	0.62	0.05	-0.84		0.36	0.29	-0.01	0.81	0.81	0.78	0.8	0.44	0.81	0.45	0.42	0.5	0.7	0.5	0.73	0.78	0.34	0.08	0.71
Total Current Assets	0.92	-0.89	-0.56	0.36		0.97	-0.33	0.44	0.7	0.79	0.51	0.41	0.67	-0.11	0.94	0.49	0.77	0.56	0.75	0.58	0.93	0.93	0.56
Total Stockholder Equity	0.93	-0.86	-0.55	0.29	0.97		-0.41	0.43	0.7	0.78	0.56	0.29	0.65	-0.19	0.96	0.54	0.79	0.55	0.72	0.56	0.93	0.91	0.62
Common Stock	-0.35	0.17	0.28	-0.01	-0.33	-0.41		-0.32	-0.4	-0.42	-0.24	-0.45	-0.41	-0.05	-0.26	-0.21	-0.45	-0.31	-0.34	-0.36	-0.21	-0.17	-0.2
Accounts Payable	0.69	-0.07	-0.82	0.81	0.44	0.43	-0.32		0.89	0.81	0.82	0.4	0.87	0.51	0.53	0.5	0.76	0.52	0.73	0.9	0.45	0.15	0.83
Good Will	0.89	-0.33	-0.92	0.81	0.7	0.7	-0.4	0.89		0.98	0.82	0.54	0.99	0.3	0.74	0.57	0.93	0.63	0.91	0.93	0.67	0.43	0.85
Intangible Assets	0.94	-0.43	-0.89	0.78	0.79	0.78	-0.42	0.81	0.98		0.81	0.59	0.97	0.19	0.79	0.6	0.94	0.64	0.93	0.88	0.73	0.54	0.79
Property Plant Equipment	0.77	-0.15	-0.78	0.8	0.51	0.56	-0.24	0.82	0.82	0.81		0.22	0.77	0.18	0.63	0.68	0.79	0.5	0.72	0.73	0.55	0.29	0.82
Long Term Debt	0.39	-0.15	-0.42	0.44	0.41	0.29	-0.45	0.4	0.54	0.59	0.22		0.58	0.24	0.17	0.1	0.41	0.33	0.6	0.54	0.17	0.18	0.07
Net Receivables	0.86	-0.29	-0.92	0.81	0.67	0.65	-0.41	0.87	0.99	0.97	0.77	0.58		0.3	0.69	0.52	0.91	0.6	0.91	0.93	0.62	0.38	0.82
Short Term Debt	0.04	0.31	-0.37	0.45	-0.11	-0.19	-0.05	0.51	0.3	0.19	0.18	0.24	0.3		-0.1	-0.15	0.16	0.57	0.14	0.48	-0.18	-0.35	0.23
Net Tangible Assets	0.95	-0.81	-0.61	0.42	0.94	0.96	-0.26	0.53	0.74	0.79	0.63	0.17	0.69	-0.1		0.59	0.83	0.57	0.75	0.63	0.95	0.87	0.76
Current Deferred Revenue	0.63	-0.28	-0.56	0.5	0.49	0.54	-0.21	0.5	0.57	0.6	0.68	0.1	0.52	-0.15	0.59		0.64	0.32	0.51	0.38	0.55	0.41	0.63
Capital Surpluse	0.9	-0.42	-0.89	0.7	0.77	0.79	-0.45	0.76	0.93	0.94	0.79	0.41	0.91	0.16	0.83	0.64		0.68	0.93	0.87	0.68	0.52	0.88
Short Long Term Debt	0.63	-0.31	-0.59	0.5	0.56	0.55	-0.31	0.52	0.63	0.64	0.5	0.33	0.6	0.57	0.57	0.32	0.68		0.61	0.69	0.43	0.33	0.58
Long Term Debt Total	0.85	-0.39	-0.81	0.73	0.75	0.72	-0.34	0.73	0.91	0.93	0.72	0.6	0.91	0.14	0.75	0.51	0.93	0.61		0.87	0.62	0.5	0.78
Long Term Investments	0.76	-0.2	-0.86	0.78	0.58	0.56	-0.36	0.9	0.93	0.88	0.73	0.54	0.93	0.48	0.63	0.38	0.87	0.69	0.87		0.48	0.27	0.81
Net Invested Capital	0.91	-0.87	-0.51	0.34	0.93	0.93	-0.21	0.45	0.67	0.73	0.55	0.17	0.62	-0.18	0.95	0.55	0.68	0.43	0.62	0.48		0.92	0.61
Net Working Capital	0.77	-0.98	-0.26	0.08	0.93	0.91	-0.17	0.15	0.43	0.54	0.29	0.18	0.38	-0.35	0.87	0.41	0.52	0.33	0.5	0.27	0.92		0.36
Capital Stock	0.79	-0.25	-0.81	0.71	0.56	0.62	-0.2	0.83	0.85	0.79	0.82	0.07	0.82	0.23	0.76	0.63	0.88	0.58	0.78	0.81	0.61	0.36

Click cells to compare fundamentals

A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

Competition

Predict Cytosorbents Crp

Operating Profit Margin Over Time

Cytosorbents Pretax Profit Margin

Pretax Profit Margin

(0.85)

At this time, Cytosorbents Crp's Pretax Profit Margin is very stable compared to the past year.

Based on the recorded statements, Cytosorbents Crp has an Operating Margin of -1.0246%. This is 97.08% lower than that of the Health Care Equipment & Supplies sector and 97.39% lower than that of the Health Care industry. The operating margin for all United States stocks is 81.4% lower than that of the firm.

Cytosorbents Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytosorbents Crp's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytosorbents Crp could also be used in its relative valuation, which is a method of valuing Cytosorbents Crp by comparing valuation metrics of similar companies.

Cytosorbents Crp is currently under evaluation in operating margin category among related companies.

Cytosorbents Crp Current Valuation Drivers

We derive many important indicators used in calculating different scores of Cytosorbents Crp from analyzing Cytosorbents Crp's financial statements. These drivers represent accounts that assess Cytosorbents Crp's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cytosorbents Crp's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	124.2M	309.4M	181.7M	67.5M	49.6M	47.1M
Enterprise Value	128.1M	239.0M	143.4M	63.6M	53.8M	93.7M

Cytosorbents Fundamentals

	Return On Equity	-0.97
	Return On Asset	-0.32
	Profit Margin	(0.78) %
	Operating Margin	(1.02) %
	Current Valuation	53.57 M
	Shares Outstanding	54.31 M
	Shares Owned By Insiders	3.20 %
	Shares Owned By Institutions	37.26 %
	Number Of Shares Shorted	1.55 M
	Price To Earning	(16.30) X
	Price To Book	2.03 X
	Price To Sales	1.30 X
	Revenue	36.35 M
	Gross Profit	20.73 M
	EBITDA	(28.53 M)
	Net Income	(28.51 M)
	Cash And Equivalents	30.16 M
	Cash Per Share	0.69 X
	Total Debt	18.31 M
	Debt To Equity	0.28 %
	Current Ratio	3.95 X
	Book Value Per Share	0.43 X
	Cash Flow From Operations	(21.66 M)
	Short Ratio	16.50 X
	Earnings Per Share	(0.64) X
	Target Price	3.63
	Number Of Employees	186
	Beta	0.62
	Market Capitalization	53.19 M
	Total Asset	53.26 M
	Retained Earnings	(282.51 M)
	Working Capital	11.16 M
	Current Asset	9.05 M
	Current Liabilities	5 M
	Net Asset	53.26 M

About Cytosorbents Crp Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cytosorbents Crp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytosorbents Crp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytosorbents Crp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Cytosorbents Crp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytosorbents Crp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytosorbents Crp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytosorbents Crp Stock:

How To Invest In Cytosorbents

Details

Is Cytosorbents Stock a good investment?

Details

What is Cytosorbents Crp's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Cytosorbents Crp Piotroski F Score and Cytosorbents Crp Altman Z Score analysis.

To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Cytosorbents Stock analysis

When running Cytosorbents Crp's price analysis, check to measure Cytosorbents Crp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytosorbents Crp is operating at the current time. Most of Cytosorbents Crp's value examination focuses on studying past and present price action to predict the probability of Cytosorbents Crp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytosorbents Crp's price. Additionally, you may evaluate how the addition of Cytosorbents Crp to your portfolios can decrease your overall portfolio volatility.

	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk

Is Cytosorbents Crp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.64)

Revenue Per Share

0.814

Quarterly Revenue Growth

(0.08)

Return On Assets

(0.32)

Return On Equity

(0.97)

The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cytosorbents Crp Stock Operating Margin

Cytosorbents Crp Company Operating Margin Analysis

Operating Margin

Operating Income

Revenue

100

Current Cytosorbents Crp Operating Margin

Cytosorbents Operating Margin Driver Correlations

Cytosorbents Pretax Profit Margin

Pretax Profit Margin

(0.85)

Cytosorbents Operating Margin Peer Comparison

Cytosorbents Crp Current Valuation Drivers

Cytosorbents Fundamentals

About Cytosorbents Crp Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Cytosorbents Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY